Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1190)	4/29/1999 12:29:00 AM
From: VeloSpeed	Read Replies (1) \| Respond to of 1826

Richard, is it too early to get excited about ASCO? While riding today, I kept mulling over this one part of the MGI-114 press release - the part that so many "quick headline-scan" investors may regret missing... "Early evidence indicates that this drug has the potential to treat a variety of solid tumors, especially those tumors that are resistant to other drugs," said Dr. Steve Weitman, a lead investigator of MGI 114 at the Institute for Drug Development, San Antonio, Texas. "Should MGI 114 prove to be as effective in humans as it has been in animal studies, it could one day touch the lives of the many thousands of Americans diagnosed with cancer each year." newsalert.com Very anxious for the conference to get underway... -VeloSpeed